Leukemia propagating cells rebuild an evolving niche in response to therapy

Cancer Cell. 2014 Jun 16;25(6):778-93. doi: 10.1016/j.ccr.2014.04.015.

Abstract

Residence of cancer-propagating cells (CPCs) within preferential microenvironmental niches has a major part in evading therapy. However, the nature of niches involved and the mechanisms protecting CPCs remain largely unknown. We addressed these issues in mouse transplantation models of acute lymphoblastic leukemia (ALL). When the engrafted leukemic cells substantially damaged adjacent microenvironment in the bone marrow (BM), after chemotherapy small foci of CPCs were retained, surrounded by sheaths of supporting cells that comprise a protective niche. We investigated patients' BM biopsies and found evidence of a similar process in patients receiving induction therapy. The efficacy of chemotherapy was enhanced by interfering with the niche formation or function. We therefore identified a therapy-induced niche that protects CPCs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Biopsy
  • Bone Marrow Cells / drug effects
  • Bone Marrow Cells / pathology
  • Cytarabine / administration & dosage
  • Cytarabine / pharmacology
  • Daunorubicin / administration & dosage
  • Daunorubicin / pharmacology
  • Disease Models, Animal
  • Humans
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Neoplastic Stem Cells / drug effects*
  • Neoplastic Stem Cells / pathology*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology*
  • Stem Cell Niche / drug effects*
  • Tumor Microenvironment / drug effects
  • Xenograft Model Antitumor Assays

Substances

  • Cytarabine
  • Daunorubicin

Associated data

  • GEO/GSE56273